UPDATE: Bank of America Raises PT on Repros Therapeutics on Higher Androxal Conviction

By: Benzinga
In a report published Wednesday, Bank of America analyst Steve Byrne reiterated a Buy rating on Repros Therapeutics (NASDAQ: RPRX ), and raised the price target from $25.00 to $35.00. In the report, Bank of America noted, “Following positive top line phase 3 data (study ‘302) for RPRX's Androxal, we
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.